New gene therapy trial offers hope for kids with rare brain disorder

NCT ID NCT04903288

First seen Oct 31, 2025 · Last updated May 10, 2026 · Updated 27 times

Summary

This study tests a gene therapy called eladocagene exuparvovec in 13 children with AADC deficiency, a rare genetic disorder that affects brain function. The therapy is given directly into the brain using a special needle. The main goals are to check safety and see if it raises levels of a key brain chemical called HVA. The study includes short-term and long-term follow-up to track benefits and side effects.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for AADC DEFICIENCY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Boston Children's Hospital

    Boston, Massachusetts, 02115, United States

  • Chaim Sheba Medical Center

    Ramat Gan, 5262000, Israel

  • Cincinnati Children's Hospital Medical Center

    Cincinnati, Ohio, 45229, United States

  • Duke University Hospital

    Durham, North Carolina, 27705, United States

  • National Taiwan University Hospital, Department of Pediatrics and Medical Genetics

    Taipei, 10041, Taiwan

  • Texas Children's Hospital

    Houston, Texas, 77030, United States

Conditions

Explore the condition pages connected to this study.